<DOC>
	<DOCNO>NCT01155765</DOCNO>
	<brief_summary>Clopidogrel administration essential patient undergo percutaneous coronary intervention , patient previous stroke , patient chronic hemodialysis via fistula patient chronic atrial fibrillation coumarin administration viable option . Patients chronic renal failure present low clopidogrel response compare normal renal function . Additionally , hemodialysis via dialysis filter cause decrease glycoprotein platelet receptor , potentially associate thienopyridine hyporesponsiveness . Clopidogrel resistant patient assess VerifyNow P2Y12 ( Accumetrics ) randomize 1:1 fashion prasugrel 10mg/day clopidogrel 150mg/day . On day 15±2 day crossover directly alternate treatment group carry , without interventing washout period . All patient undergo platelet reactivity assessment , documentation major adverse cardiac event documentation serious adverse event ( stroke , bleed ) day 15 day 30 .</brief_summary>
	<brief_title>Prasugrel Versus High Dose Clopidogrel Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>1 . Age ≥18 year old 2 . History chronic renal failure hemodialysis least 6 month 3 . Under clopidogrel 75mg/day treatment least 7 day randomization 4 . Informed consent obtain write 1 . Treatment investigational agent ( include placebo ) device within 30 day prior randomization plan use investigational agent device prior Day 30 visit . 2 . Pregnancy 3 . Breastfeeding 4 . Inability give inform consent high likelihood unavailable Day 30 follow . 5 . Malignancy 6 . Acute coronary syndrome hemodynamic instability within 30 day prior randomization 7 . Requirement oral anticoagulant prior Day 30 visit 8 . Requirement discontinuation thienopyridine treatment prior Day 30 visit 9 . Treatment IIb/IIIa inhibitor within 30 day prior randomization plan administration prior Day 30 visit 10 . Known hypersensitivity prasugrel clopidogrel . 11 . History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 6 month . 12 . Other bleed diathesis , consider investigator high risk bleed thienopyridine therapy . 13 . Any previous history ischemic stroke , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) . 14 . Thrombocytopenia ( &lt; 100.000 / μL ) randomization 15 . Known liver failure ( bilirubin &gt; 2mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Clopidogrel Resistance</keyword>
	<keyword>prasugrel</keyword>
	<keyword>Hemodialysis</keyword>
</DOC>